(Reuters) – Novartis’s third-quarter adjusted operating profit rose 10% as the Swiss drugmaker lifted its peak sales estimate for its two most important pharmaceuticals.
Operating profit, adjusted for special items, rose 10% to $4.47 billion, driven by higher sales of arthritis and psoriasis drug Cosentyx and heart failure treatment Entresto.
In a statement on Tuesday, Novartis said it increased its peak sales guidance for Cosentyx to at least $7 billion and for Entresto to at least $5.0 billion.
(Reporting by Ludwig Burger; Editing by Michael Shields)
